Am J Obstet Gynecol

1. KALRA A, Ganesan S, Sia JJY, Papalois KB, et al
   Uptake and patient-related outcomes of mainstreaming genetic testing: a systematic review and meta-analysis.
   Am J Obstet Gynecol. 2025;233:276-291.
   

   >> Share

   
   

   
   Br J Cancer

2. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
   Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
   Br J Cancer. 2025;133:874-885.
   

   >> Share

   
   

   
   Eur J Obstet Gynecol Reprod Biol

3. CHENG X, Liu P, Zhao Q, Ye L, et al
   Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China.
   Eur J Obstet Gynecol Reprod Biol. 2025;314:114707.
   

   >> Share

   
   

   
   Int J Cancer

4. WANG L, Zang Y, Dejenie R, Bing J, et al
   The role of cytokines in ovarian cancer drug resistance.
   Int J Cancer. 2025 Sep 19. doi: 10.1002/ijc.70099.
   

   >> Share

   
   

   
   Proc Natl Acad Sci U S A

5. CHOWDHURY SR, Parikh CN, Kaur AN, DeMarco KD, et al
   PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors.
   Proc Natl Acad Sci U S A. 2025;122:e2514948122.
   

   >> Share

   
   
6. ALENCAR GF, Mohamed AO, Burnett MG, Jean SS, et al
   Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2419888122.
   

   >> Share

   
   

   
   Tumour Biol

7. BRUM MCM, Squiavinato ACMS, Carneiro LDT, Ferreira LB, et al
   Osteopontin-c gene expression and subcellular localization in ovarian cancer cells: Implications for prognosis and therapeutic responses.
   Tumour Biol. 2025;47:14230380251375818.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share